Recent Finacing
Recent Raise
Immatics develops and clinically advances T-cell–based cancer therapies—including TCR-engineered adoptive cell therapies, bispecific TCRs, and multi‑peptide vaccines—using XPRESIDENT antigen discovery to target intracellular tumor peptides in HLA‑matched patients.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
